Discounted Cash Flow
Akebia Therapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $1.5m | $-135.7m | $55.2m | -8843.5% | — |
| 2017 | $181.2m (11706.3%) | $-73.7m (45.7%) | $-57.8m (-204.6%) | -40.7% (99.5%) | $-1.77 |
| 2018 | $207.7m (14.6%) | $-143.6m (-94.9%) | $-99.1m (-71.5%) | -69.1% (-70.0%) | $-2.47 (-39.5%) |
| 2019 | $335.0m (61.3%) | $-279.7m (-94.8%) | $-264.1m (-166.5%) | -83.5% (-20.8%) | $-2.36 (4.5%) |
| 2020 | $295.3m (-11.8%) | $-383.5m (-37.1%) | $-110.7m (58.1%) | -129.9% (-55.5%) | $-2.77 (-17.4%) |
| 2021 | $213.6m (-27.7%) | $-282.8m (26.2%) | $-253.0m (-128.6%) | -132.4% (-2.0%) | $-1.70 (38.6%) |
| 2022 | $292.5m (36.9%) | $-94.2m (66.7%) | $-73.3m (71.0%) | -32.2% (75.7%) | $-0.52 (69.4%) |
| 2023 | $194.6m (-33.5%) | $-51.9m (44.9%) | $-23.4m (68.1%) | -26.7% (17.2%) | $-0.28 (46.2%) |
| 2024 | $160.2m (-17.7%) | $-69.4m (-33.7%) | $-40.7m (-74.0%) | -43.3% (-62.4%) | $-0.33 (-17.9%) |
| 2025 | $236.2m (47.5%) | $-5.3m (92.3%) | $-5.3m (86.9%) | -2.3% (94.8%) | $-0.02 (93.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.